There are 2934 resources available
Proffered Paper – Melanoma and other skin tumours - Invited Discussant LBA66, LBA67 and 1310O
Presenter: Bartosz Chmielowski
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Slides
Webcast
2545 - 5-year survival outcomes of the CheckMate 067 phase 3 trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma
Presenter: James Larkin
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Results of ESMO survey/collection of data regarding shortage essential medicines in Europe and beyond, along with EIU reports on specific countries
Presenter: Alexandru Eniu
Session: Essential medicines, but not always available
Resources:
Slides
Webcast
Case study: State of play in Pakistan
Presenter: Zeba Aziz
Session: Essential medicines, but not always available
Resources:
Slides
Webcast
WHO perspective: What can be done to mitigate shortages?
Presenter: Nicola Magrini
Session: Essential medicines, but not always available
Resources:
Slides
Webcast
4844 - EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.
Presenter: Christopher Hoimes
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
4397 - An adaptive, biomarker directed platform study in metastatic urothelial cancer (BISCAY) with durvalumab in combination with targeted therapies
Presenter: Thomas Powles
Session: Proffered Paper 1 – Genitourinary tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1691 - PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors
Presenter: Benedetta Pellegrino
Session: Proffered Paper – Translational research
Resources:
Abstract
Slides
Webcast
2339 - Interferon ɣ (IFN-ɣ) gene signature and tryptophan 2,3-dioxygenase 2 (TDO2) gene expression: a potential predictive composite biomarker for linrodostat mesylate (BMS-986205; indoleamine 2,3-dioxygenase 1 inhibitor [IDO1i]) + nivolumab (NIVO)
Presenter: Jason Luke
Session: Proffered Paper – Translational research
Resources:
Abstract
Slides
Webcast
2801 - Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Proffered Paper – Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast